The Shmunis School of Biomedicine and Cancer Research, Cell Biology Division, George Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel; Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel.
School of Neurobiology, Biochemistry and Biophysics, George Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel.
J Biol Chem. 2021 Nov;297(5):101299. doi: 10.1016/j.jbc.2021.101299. Epub 2021 Oct 11.
The Sigma-1 receptor (S1R) is a transmembrane protein with important roles in cellular homeostasis in normal physiology and in disease. Especially in neurodegenerative diseases, S1R activation has been shown to provide neuroprotection by modulating calcium signaling, mitochondrial function and reducing endoplasmic reticulum (ER) stress. S1R missense mutations are one of the causes of the neurodegenerative Amyotrophic Lateral Sclerosis and distal hereditary motor neuronopathies. Although the S1R has been studied intensively, basic aspects remain controversial, such as S1R topology and whether it reaches the plasma membrane. To address these questions, we have undertaken several approaches. C-terminal tagging with a small biotin-acceptor peptide and BirA biotinylation in cells suggested a type II membrane orientation (cytosolic N-terminus). However, N-terminal tagging gave an equal probability for both possible orientations. This might explain conflicting reports in the literature, as tags may affect the protein topology. Therefore, we studied untagged S1R using a protease protection assay and a glycosylation mapping approach, introducing N-glycosylation sites. Both methods provided unambiguous results showing that the S1R is a type II membrane protein with a short cytosolic N-terminal tail. Assessments of glycan processing, surface fluorescence-activated cell sorting, and cell surface biotinylation indicated ER retention, with insignificant exit to the plasma membrane, in the absence or presence of S1R agonists or of ER stress. These findings may have important implications for S1R-based therapeutic approaches.
Sigma-1 受体(S1R)是一种跨膜蛋白,在正常生理和疾病中的细胞内稳态中具有重要作用。特别是在神经退行性疾病中,S1R 的激活已被证明通过调节钙信号、线粒体功能和减少内质网(ER)应激来提供神经保护。S1R 错义突变是神经退行性肌萎缩侧索硬化症和远端遗传性运动神经元病的原因之一。尽管 S1R 已经被深入研究,但基本方面仍存在争议,例如 S1R 的拓扑结构以及它是否到达质膜。为了解决这些问题,我们采取了几种方法。用小生物素接受肽和 BirA 生物素酰化在细胞中对 C 端进行标记,表明存在 II 型膜取向(胞质 N 端)。然而,N 端标记给出了两种可能取向的相同概率。这可能解释了文献中相互矛盾的报告,因为标签可能会影响蛋白质的拓扑结构。因此,我们使用蛋白酶保护测定法和糖基化图谱方法研究了未标记的 S1R,引入了 N-糖基化位点。这两种方法都提供了明确的结果,表明 S1R 是一种 II 型膜蛋白,具有短的胞质 N 端尾部。糖基化处理、表面荧光激活细胞分选和细胞表面生物素化的评估表明,在没有或存在 S1R 激动剂或 ER 应激的情况下,S1R 会保留在内质网中,很少有部分会到达质膜。这些发现可能对基于 S1R 的治疗方法具有重要意义。